[go: up one dir, main page]

CN102993259A - Preparation method of fulvestrant intermediate - Google Patents

Preparation method of fulvestrant intermediate Download PDF

Info

Publication number
CN102993259A
CN102993259A CN 201110278101 CN201110278101A CN102993259A CN 102993259 A CN102993259 A CN 102993259A CN 201110278101 CN201110278101 CN 201110278101 CN 201110278101 A CN201110278101 A CN 201110278101A CN 102993259 A CN102993259 A CN 102993259A
Authority
CN
China
Prior art keywords
under
compound
site
fulvestrant
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 201110278101
Other languages
Chinese (zh)
Inventor
陈玮琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 201110278101 priority Critical patent/CN102993259A/en
Publication of CN102993259A publication Critical patent/CN102993259A/en
Pending legal-status Critical Current

Links

Landscapes

  • Steroid Compounds (AREA)

Abstract

The invention provides a novel synthetic method of a fulvestrant intermediate. The technical scheme is as follows: the novel synthetic method comprises the following steps of: carrying out 7-site alkylation addition on 6-carbonyl estradiol diacetate and 1,9-halogenated bi-nonane under the action of potassium tert-butoxide; then carrying out hydrogenation reduction by using palladium carbon, so as to remove 6-site carbonyl; subsequently, condensing the product obtained from the former step with penta-fluorin amyl alcohol methyl sulfonyl ester under an alkaline condition; and finally, hydrolyzing 3-site and 17-site ester groups. The fulvestrant intermediate can be obtained by only four steps of reaction in all, the reaction condition is moderate, the raw materials are all domestic chemical products, and the preparation method is easy to operate and low in cost, and is suitable for industrial production.

Description

A kind of preparation method of fulvestrant intermediate
Technical field
The present invention is a kind of preparation method of fulvestrant intermediate, and (formula V) is as follows for its structure:
Figure BSA00000576307100011
Background technology
Fulvestrant is a kind of estrogen antagonist, and it reduces its effect take the female acceptor of breast cancer cell as target spot, but is the antiestrogen of unique widespread use after tamoxifen effect failure, is the choice drug for the treatment of at present hormone-sensitive type mammary cancer.Wherein relate to a crucial intermediate (7a, 17b)-7-[9-[(4,4,5,5,5-, five fluorine amyl groups) sulphur] nonyl] female steroid-1,3,5 (10)-triolefins-3, the 17-glycol, its purity is very large to the quality influence of fulvestrant.Now existing more bibliographical information its synthetic as,
European patent EP 0138504 and US Patent No. 4659516 have been reported the general synthetic method with the fulvestrant similar compound, and its crucial synthetic method is that 7 form replaces in its structural formula.This method step is longer, and yield is very undesirable.World patent WO0232922 and WO03031399 had reported again its special route that improves afterwards, and its step is greatly reduced, and yield also increases.
The described synthetic route of US Patent No. 20060030552 and WO2006015081 then effectively reduces the ratio of the isomer of 7 bit formats reaction, but used raw material is still expensive, and cost is very high.
US Patent No. 2010174101 has been used different composition principles 7 alkylations, has also obtained certain achievement, but this route conditions is harsh, and yield is lower, is not suitable for large-scale production.
Nowadays fulvestrant usage quantity and range of application rapid growth for this reason, need to find a kind ofly can overcome above problem, can mass-producing synthesize the method for highly purified fulvestrant intermediate.
Summary of the invention
The invention provides one very simply effectively, the method for the fulvestrant key intermediate that is produced on a large scale.Use 6-carbonyl estradiol diacetate esters and 1,7 alkylation additions occur in 9-dihalo nonane under the potassium tert.-butoxide effect, and then use palladium carbon hydrogenating reduction to remove 6 carbonyls, subsequently under alkaline condition with the ester condensation of Pentafluorobenzyl pentanol methylsulfonyl, be hydrolyzed at last 3 and 17 ester groups.Altogether only need the reaction of 4 steps, it is as follows just can to obtain fulvestrant intermediate synthetic line:
Figure BSA00000576307100031
Detailed description:
1) in the solvent such as THF of drying, under the suitable temperature as-40-0 ℃ between, under the effect of highly basic, make 7 deprotonations of 6-carbonyl estradiol diacetate esters (formula I), with 1,9-dihalo nonane such as 1,9-, two bromononane generation addition reactions.Its substitution product is purer single optical isomer under lower temperature, and after obtaining Compound I I and using column chromatography purification, the HPLC purity is more than 95%, and also purifying not directly carries out the next step.
2) in acidic medium such as acetic acid, use 6 carbonyls of palladium carbon hydrogenating reduction.Temperature of reaction can be finished between 20-100 ℃ more rapidly, obtains the formula III compound.
3) the formula III compound after 6-20 hour, behind the generation mercaptan, obtains product IV with the ester condensation of Pentafluorobenzyl pentanol methylsulfonyl with the thiocarbamide back flow reaction again under alkaline condition in toluene
4) compound IV is hydrolyzed under strong alkaline condition and obtains fulvestrant intermediate V, and purity can reach more than 95% behind the use rapid column chromatography
Specific embodiments:
Embodiment 1
In reaction flask, add 6-carbonyl estradiol diacetate esters and THF, cool to 0 ℃, slowly add potassium tert.-butoxide, add and continue reaction 1 hour.Then continue to cool to-20 ℃, drip the THF solution of 1,9-, two bromononanes, add and slowly be warmed up to 0 ℃ afterwards.React after raw material finishes less than 1%. reactions and add entry and methylene dichloride, separate the upper strata after, wash 3 times.40 ℃ of vacuum concentration obtain yellow liquid, and purifying does not directly carry out next step.
Embodiment 2
Products obtained therefrom among the embodiment 1 is joined in the reactor, pass into the nitrogen replacement air 3 times after adding acetic acid, add again palladium carbon, begin to warm to 50 ℃, change nitrogen into hydrogen, be reacted to raw material less than after 1%.Cooling, filter out catalyzer after, add entry and toluene, after organic layer uses salt water washing 3 times, 45 ℃ of vacuum concentration, the oily matter that obtains obtains weak yellow liquid after using rapid column chromatography.
Embodiment 3
Embodiment 2 products obtained therefroms are joined in the toluene, add thiocarbamide, refluxed 12 hours, then cooling is concentrated into dried.Add the sticky solid that the DMF dissolving obtains under the room temperature, then add 20% aqueous sodium hydroxide solution, under rapid stirring, add subsequently Pentafluorobenzyl pentanol methylsulfonyl ester, reacted 30 minutes, use TLC (ethyl acetate and the agent of sherwood oil Mixed Expansion) to follow the tracks of raw material to disappearing.React complete rear adding toluene and water, organic layer saturated common salt water washing 3 times.Be concentrated into do after, directly carry out next step
Embodiment 4
Embodiment 3 resulting products are added in the reactor, add methyl alcohol and potassium hydroxide aqueous solution, 30 ℃ were reacted 2 hours, use TLC (ethyl acetate and the agent of sherwood oil Mixed Expansion) to follow the tracks of raw material to disappearing, react and add entry and ethyl acetate after complete, organic layer washes 3 times with water after nearly neutrality, is concentrated into dried, obtain a faint yellow oily thing after using rapid column chromatography, content is greater than 95%.

Claims (2)

1. a structural formula is suc as formula the compound of V:
Figure FSA00000576982500011
2. the preparation method of a fulvestrant intermediate is characterized in that, may further comprise the steps:
1) in the solvent such as THF of drying, under the suitable temperature as-40-0 ℃ between, under the effect of highly basic, make 7 deprotonations of 6-carbonyl estradiol diacetate esters (formula I), with 1,9-dihalo nonane such as 1,9-, two bromononane generation addition reactions.Its substitution product is purer single optical isomer under lower temperature, and after obtaining Compound I I and using column chromatography purification, the HPLC purity is more than 95%, and also purifying not directly carries out the next step.
2) in acidic medium such as acetic acid, use 6 carbonyls of palladium carbon hydrogenating reduction.Temperature of reaction can be finished between 20-100 ℃ more rapidly, obtains the formula III compound.
3) the formula III compound after 6-20 hour, behind the generation mercaptan, obtains product IV with the ester condensation of Pentafluorobenzyl pentanol methylsulfonyl with the thiocarbamide back flow reaction again under alkaline condition in toluene
4) compound IV is hydrolyzed under strong alkaline condition and obtains fulvestrant intermediate V, and purity can reach more than 95% behind the use rapid column chromatography.
CN 201110278101 2011-09-15 2011-09-15 Preparation method of fulvestrant intermediate Pending CN102993259A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110278101 CN102993259A (en) 2011-09-15 2011-09-15 Preparation method of fulvestrant intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110278101 CN102993259A (en) 2011-09-15 2011-09-15 Preparation method of fulvestrant intermediate

Publications (1)

Publication Number Publication Date
CN102993259A true CN102993259A (en) 2013-03-27

Family

ID=47922423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110278101 Pending CN102993259A (en) 2011-09-15 2011-09-15 Preparation method of fulvestrant intermediate

Country Status (1)

Country Link
CN (1) CN102993259A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965280A (en) * 2014-05-21 2014-08-06 天津孚音生物科技发展有限公司 Preparation method of fulvestrant intermediate
WO2015181116A1 (en) * 2014-05-26 2015-12-03 Crystal Pharma, S.A.U. Process and intermediades for the preparation of 7-alkylated steroids
CN107286213A (en) * 2016-03-31 2017-10-24 杭州共泽医药科技有限公司 A kind of preparation method of fulvestrant intermediate
CN108264534A (en) * 2016-12-31 2018-07-10 天津金耀集团有限公司 A kind of preparation method of fulvestrant
CN110128310A (en) * 2018-02-09 2019-08-16 鲁南制药集团股份有限公司 A kind of fulvestrant intermediate
CN111377990A (en) * 2018-12-29 2020-07-07 江苏豪森药业集团有限公司 Preparation method of fulvestrant related substance
WO2022257895A1 (en) * 2021-06-09 2022-12-15 上海弼领生物技术有限公司 Intermediate for preparing fulvestrant and preparation method therefor

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965280A (en) * 2014-05-21 2014-08-06 天津孚音生物科技发展有限公司 Preparation method of fulvestrant intermediate
CN103965280B (en) * 2014-05-21 2016-04-20 天津孚音生物科技发展有限公司 A kind of preparation method of fulvestrant intermediate
WO2015181116A1 (en) * 2014-05-26 2015-12-03 Crystal Pharma, S.A.U. Process and intermediades for the preparation of 7-alkylated steroids
CN107286213A (en) * 2016-03-31 2017-10-24 杭州共泽医药科技有限公司 A kind of preparation method of fulvestrant intermediate
CN108264534A (en) * 2016-12-31 2018-07-10 天津金耀集团有限公司 A kind of preparation method of fulvestrant
CN108264534B (en) * 2016-12-31 2022-06-14 天津金耀集团有限公司 Preparation method of fulvestrant
CN110128310A (en) * 2018-02-09 2019-08-16 鲁南制药集团股份有限公司 A kind of fulvestrant intermediate
CN111377990A (en) * 2018-12-29 2020-07-07 江苏豪森药业集团有限公司 Preparation method of fulvestrant related substance
WO2022257895A1 (en) * 2021-06-09 2022-12-15 上海弼领生物技术有限公司 Intermediate for preparing fulvestrant and preparation method therefor

Similar Documents

Publication Publication Date Title
CN102993259A (en) Preparation method of fulvestrant intermediate
CN100427497C (en) A method for chemically synthesizing salidroside
CN103396451B (en) The preparation method of tenofovir disoproxil fumarate intermediate
CN103319560A (en) Preparation method of ursodeoxycholic acid
CN102321038B (en) Improved valsartan preparation method
CN101570550A (en) Method for synthesizing chiral ferrocene diphosphine ligand
CN102952135A (en) Method for synthesizing hepatitis B medicine entecavir
CN107382712A (en) A kind of preparation method of 1,10 decanedioic acid
CN104557845A (en) Method for preparing lubiprostone compound
CN112062767A (en) Preparation method and intermediate of rumepilone
CN110183445A (en) The synthetic method of Moxifloxacin and its derivative
CN103254265B (en) Abiraterone acetate trifluoroacetate and its preparation method and application
CN105693802A (en) Preparation method of 16 beta-methyl steroid
CN105693803A (en) Method for preparing progesterone
CN108129430A (en) A kind of synthetic method of Li Tasite intermediates
CN101195602B (en) 1-deoxidization nojiri toxin derivant, production method and uses thereof
CN103113288A (en) Synthesis method of octahydro-cyclopenta[c]pyrrole carboxylic acid derivative
CN112939814B (en) Preparation method of deuterated dacarbazine intermediate
CN103588842A (en) Synthetic method of betamethasone or prednisolone intermediate
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN102219792A (en) Novel method for preparing prasugrel
CN103387595B (en) A kind of preparation method of prednisolone
CN107216332A (en) The synthetic method of (6H) the formic acid base ester of 7 methylol of the tert-butyl group, 7,8 dihydro 4H pyrazolos diazepine 5
CN111979287A (en) Preparation method of 7-phenylacetylamino-3-nor-3-cephem-4-carboxylic acid
CN106316935A (en) Preparation method of Abemaciclib intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
DD01 Delivery of document by public notice

Addressee: Chen Weilin

Document name: Notification of before Expiration of Request of Examination as to Substance

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130327